|
Heart failure
|
0.060 |
Biomarker
|
disease |
BEFREE |
KLF15 may constitute an efficient candidate drug for the treatment of heart failure and other cardiovascular diseases.
|
28336438 |
2017 |
|
Heart failure
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We show in human heart samples that KLF15 is induced after birth and reduced in heart failure, a myocardial expression pattern that parallels reliance on lipid oxidation.
|
24407292 |
2014 |
|
Heart failure
|
0.060 |
Biomarker
|
disease |
BEFREE |
Mice deficient in Klf15 develop heart failure and aortic aneurysms in a p53-dependent and p300 acetyltransferase-dependent fashion.
|
20375365 |
2010 |
|
Hypertensive disease
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Then, an in vitro study of hypertension due to rotational force was conducted, and an increase in fibrosis markers and decrease in KLF15 levels were determined after application of 4 mmHg pressure in primary cultured human podocytes.
|
31697927 |
2020 |
|
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
miR-190a-5p participates in the regulation of hypoxia-induced pulmonary hypertension by targeting KLF15 and can serve as a biomarker of diagnosis and prognosis in chronic obstructive pulmonary disease complicated with pulmonary hypertension.
|
30538440 |
2019 |
|
Hypertensive disease
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Strategies including overexpression of KLF15 or inhibition of SENP1 may represent novel therapeutic targets for pulmonary hypertension.
|
29472234 |
2018 |
|
Left Ventricular Hypertrophy
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
It also discusses our recent paper that described the contribution of genetic variants in <i>KLF15</i> to the development of LVH and heart failure in high-risk patients.
|
29702551 |
2018 |
|
Left Ventricular Hypertrophy
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
It is unknown if KLF15 expression is changed in CKD induced LVH, or whether expression is modulated by blood pressure reduction using angiotensin converting enzyme (ACE) inhibition.
|
29970016 |
2018 |
|
Hypertensive disease
|
0.040 |
GeneticVariation
|
group |
BEFREE |
The KLF15 SNP rs9838915 A allele was associated in a dominant manner with LV mass before (P=0.003) and after (P=0.001) adjustment for age, gender, body mass index (BMI) and hypertension, and with adjusted septal (P<0.0001) and posterior (P=0.004) wall thickness.LVH was present in 35% of patients.
|
28400202 |
2017 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Moreover, bioinformatics and luciferase reporter gene assays confirmed that miR-4262 targeted the mRNA 3'-UTR region of KLF6 and KLF15, two characterized tumor suppressor genes. miR-4262 suppressed protein levels of KLF6 and KLF15 in MDA-MB-231 cells, and the suppression could be rescued by the transfection of pcDNA-KLF6 and -KLF15.
|
27629257 |
2017 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Expression of KLF15 was found to be abnormally high in LADC tissues and cells compared with adjacent non-tumorous tissues, and was correlated with tumor TNM stage and tumor differentiation (<i>P</i> = 0.003, <i>P</i> = 0.001, respectively).
|
29299121 |
2017 |
|
Left Ventricular Hypertrophy
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Genetic Variation in Kruppel like Factor 15 Is Associated with Left Ventricular Hypertrophy in Patients with Type 2 Diabetes: Discovery and Replication Cohorts.
|
28400202 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The characterization of novel EWSR1-KLF15 fusion transcripts carries important diagnostic implications, as well as clues to understand the pathogenesis of these neoplasms.
|
26523541 |
2016 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
KLF15 in breast cancer: a novel tumor suppressor?
|
25869021 |
2015 |
|
Left Ventricular Hypertrophy
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of KLF15 and GLUT4 were decreased at the left ventricular hypertrophy and congestive heart failure stage in a rat model.
|
19720047 |
2009 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
KLF15 may therefore be an effective therapeutic target for the treatment of heart failure and other cardiovascular diseases.
|
30831134 |
2019 |
|
Kidney Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Krüppel-like Factor 15: A Potential Therapeutic Target For Kidney Disease.
|
31523196 |
2019 |
|
Renal fibrosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Loss of KLF4 and KLF15 promotes renal fibrosis, while fibrotic kidneys have increased KLF5 and KLF6 expression.
|
30662001 |
2019 |
|
Kidney Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Inducing podocyte-specific <i>KLF15</i> attenuates kidney injury by directly and indirectly upregulating genes critical for podocyte differentiation, suggesting that <i>KLF15</i> induction might be a potential strategy for treating proteinuric kidney disease.
|
30143559 |
2018 |
|
Kidney Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Krüppel‑like factor 15 (KLF15) has a role in numerous pathological processes, including nephropathy, abnormal glucose metabolism and myocardial injury.
|
29956764 |
2018 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
KLF15 may constitute an efficient candidate drug for the treatment of heart failure and other cardiovascular diseases.
|
28336438 |
2017 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
<b>Background</b> KLF15 (Krüppel-like factor 15) was reported to be involved in a lot of cardiovascular diseases.
|
26600407 |
2017 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Mice lacking Klf15 in adipose tissue (AK15KO) display decreased adiposity and are protected from diet-induced obesity.
|
29241541 |
2017 |
|
Renal fibrosis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Compared with the control group, the murine model of Ang II-induced renal fibrosis demonstrated a significant decrease in renal KLF15 expression at 4 weeks and presented with progressive renal fibrosis at 6 weeks.
|
29179208 |
2017 |
|
Renal fibrosis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Here, we tested whether Klf15 mRNA and protein expression are reduced in late stages of fibrosis in mice that underwent unilateral ureteric obstruction, a model of progressive renal fibrosis.
|
28651950 |
2017 |